Hangzhou DAC Biotechnology Co., Ltd.

The increasing global incidence of gastric cancer is a major factor driving the demand for gastric cancer diagnostics. The market is also being fueled by the rising prevalence of GERD and other stomach-related conditions, along with the growing number of stomach infections such as H. Pylori and gastroenteritis. Additionally, the surge in obesity and smoking, which are linked to the development of stomach cancer, are significant contributors to the market's growth during the forecast period from 2024 to 2030. LAS VEGAS, Sept. 3, 2024 /PRNewswire/ -- DelveInsight's Gastric Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading gastric cancer diagnostics companies' market shares, challenges, gastric cancer diagnostics market drivers, barriers, trends, and key market gastric cancer diagnostics companies in the market. Key Takeaways from the Gastric Cancer Diagnostics Market Report As per DelveInsight estimates, North America is anticipated to dominate the global gastric cancer diagnostics market during the forecast period. In the product type segment of the gastric cancer diagnostics market, the reagents & kits category generated a significant revenue share in the gastric cancer diagnostics market in 2023. Notable gastric cancer diagnostics companies such as Abbott, BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Pillar Biosciences Inc., Hologic, Inc., CD Genomics, Natera, Inc., Biodesix, Illumina, Inc., Quest Diagnostics, Agilent Technologies, Inc., FUJIFILM Holdings Corporation, NeoGenomics Laboratories, Guardant Health, Myriad Genetics, Inc., Invitae Corporation, Danaher, and several others, are currently operating in the gastric cancer diagnostics market. In March 2024, AI Medical Service Inc. announced that it had launched gastroAI-model G, an AI-based endoscopic diagnostic support device that operates within the stomach. The diagnostic device operates by scanning for potential lesions, utilizing images derived from the video processor of the endoscopy system. Upon determining that a lesion appears suspicious for early gastric cancer and requires additional evaluation, the program notifies the physician and offers diagnostic support by presenting a highlighted area within the endoscopic display. In November 2023, Dedalus Group in collaboration with Ibex Medical Analytics, announced the launch of a fully integrated AI-powered digital pathology solution for gastric cancer diagnosis. In August 2023, Mirxes Pte Ltd announced that its flagship product GASTROClear, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). It is a molecular blood test for the early detection of gastric cancer that helps to cure cancer with affordable treatment. To read more about the latest highlights related to the gastric cancer diagnostics market, get a snapshot of the key highlights entailed in the Global Gastric Cancer Diagnostics Market Report Gastric Cancer Diagnostics Overview Gastric cancer, or stomach cancer, is typically diagnosed through a combination of clinical evaluation, imaging techniques, and tissue biopsy. The diagnostic process often begins with a patient's history and physical examination, focusing on symptoms like persistent indigestion, weight loss, and abdominal pain. Imaging studies, such as upper gastrointestinal endoscopy, are crucial as they allow direct visualization of the stomach lining. During an endoscopy, a flexible tube with a camera is inserted through the mouth into the stomach, enabling doctors to identify suspicious lesions or tumors. Additional imaging techniques, such as computed tomography (CT) scans or positron emission tomography (PET) scans, may be used to determine the extent of the cancer and to detect possible metastasis to other organs. Confirming a diagnosis of gastric cancer requires a biopsy, where tissue samples are taken during an endoscopy and examined under a microscope for cancerous cells. Histopathological analysis of the biopsy helps determine the type and grade of the cancer, which is critical for guiding treatment options. Molecular testing on the biopsy sample can also identify specific genetic mutations or protein expressions, such as HER2, which may influence targeted therapy decisions. Blood tests for tumor markers like carcinoembryonic antigen (CEA) and CA 19-9 are sometimes used to support diagnosis or monitor treatment response, although these markers are not specific to gastric cancer. Early and accurate diagnosis is essential in improving the prognosis and survival rates for patients with gastric cancer. Gastric Cancer Diagnostics Market Insights In 2023, North America held the largest share of the gastric cancer diagnostics market. This dominance is attributed to the increasing prevalence of gastric cancer and related stomach diseases, along with the region's growing geriatric population and advancements in early cancer detection technologies. Data from the American Cancer Society, published in January 2024, predicts approximately 26,890 new cases of stomach cancer in the United States for 2024, with 16,160 cases among men and 10,730 among women. Stomach cancer accounts for about 1.5% of all new cancer diagnoses annually in the country. The higher incidence of gastric cancer among older adults is linked to age-related risk factors such as stomach infections and gastroesophageal reflux disease (GERD). As a result, the expanding elderly population is expected to drive the growth of the gastric cancer diagnostics market in the region. In March 2024, Ibex Medical Analytics launched Galen, an AI-powered diagnostic platform that offers accurate cancer diagnoses, reduces manual tasks, and is used for diagnosing gastric cancer, H. pylori, and other gastric lesions like adenoma and low-grade dysplasia. This increase in R&D activities by major players to develop advanced diagnostic solutions is expected to further boost the North American gastric cancer diagnostics market. To know more about why North America is leading the market growth in the gastric cancer diagnostics market, get a snapshot of the Gastric Cancer Diagnostics Market Outlook Gastric Cancer Diagnostics Market Dynamics The gastric cancer diagnostics market is evolving rapidly, driven by technological advancements, increasing awareness, and a growing focus on early detection. Gastric cancer, which remains one of the leading causes of cancer-related mortality worldwide, particularly in Asia and Eastern Europe, has led to a pressing need for improved diagnostic methods. Traditional diagnostic techniques like endoscopy and biopsy are now being complemented and, in some cases, replaced by innovative, non-invasive technologies such as liquid biopsy, molecular diagnostics, and advanced imaging techniques. These new modalities offer the potential for earlier detection, more accurate staging, and better monitoring of disease progression, which is critical for improving patient outcomes. A significant dynamic in the market is the integration of molecular diagnostics, including next-generation sequencing (NGS), which allows for the detection of specific genetic mutations and biomarkers associated with gastric cancer. These advancements are not only enhancing the precision of diagnosis but also paving the way for personalized medicine, where treatment can be tailored based on an individual's genetic profile. The push towards personalized medicine is further fueling the demand for diagnostic tools that can provide comprehensive genomic data, leading to an increase in partnerships between diagnostic companies and pharmaceutical firms aiming to develop targeted therapies. Furthermore, the rise of artificial intelligence and machine learning in diagnostics is another key trend shaping the gastric cancer diagnostics market. AI and ML are being integrated into imaging and pathology tools to improve the accuracy of cancer detection and reduce the chances of human error. These technologies can analyze large datasets, identify patterns, and make predictions that can assist clinicians in making more informed decisions. The growing adoption of AI-driven diagnostic platforms is expected to enhance the efficiency of gastric cancer screening programs and reduce the time required for diagnosis. The market is also influenced by the increasing prevalence of gastric cancer in aging populations, particularly in regions with high incidence rates. This demographic shift is expected to drive the demand for more accessible and cost-effective diagnostic solutions. Governments and healthcare organizations in these regions are investing in public health initiatives aimed at improving cancer screening and early detection rates, which is likely to further boost the market for diagnostic products and services. However, the market faces challenges, such as high costs associated with advanced diagnostic technologies and the need for specialized expertise to interpret complex diagnostic results. Additionally, disparities in healthcare infrastructure and access to advanced diagnostics between developed and developing regions may limit market growth in certain areas. Despite these challenges, the overall outlook for the gastric cancer diagnostics market remains positive, with continuous innovations and increasing emphasis on early detection poised to significantly impact the landscape in the coming years. Get a sneak peek at the gastric cancer diagnostics market dynamics @ Gastric Cancer Diagnostics Market Dynamics Analysis Gastric Cancer Diagnostics Market Assessment Gastric Cancer Diagnostics Market Segmentation Gastric Cancer Diagnostics Market Segmentation By Product Type: Instruments, Reagents & Kits Gastric Cancer Diagnostics Market Segmentation By Test Test: Imaging Test [Upper Endoscopy, Barium Swallow/X-Rays, CT Scan, Laparoscopy, MRI, Stomach Ultrasound, and Others], Laboratory Test [Biopsy, Blood Test, and Others] Gastric Cancer Diagnostics Market Segmentation By End Users: Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Diagnostic Centers, and Others Gastric Cancer Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the gastric cancer diagnostics market are set to emerge as the trendsetter explore @ Gastric Cancer Diagnostics Companies Table of Contents Interested in knowing the gastric cancer diagnostics market by 2030? Click to get a snapshot of the Gastric Cancer Diagnostics Market Trends Related Reports Gastric Cancer Market Gastric Cancer Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key gastric cancer companies, including Hanmi Pharmaceuticals, Merck, Minneamrita Therapeutics, Taiho Pharmaceuticals, Bayer, among others. Gastric Cancer Pipeline Gastric Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key gastric cancer companies, including BeiGene, Linton Pharm Co. Ltd., RAPT Therapeutics, Leap Therapeutics, Idience, Bolt Biotherapeutics, Hubro Therapeutics, Immunocore, Ambrx, Hangzhou DAC Biotech, Beijing Immunoah Pharma Tech, Base Therapeutics, Nanjing KAEDI Biotech, HiberCell, Transcenta Holding, Suzhou Zelgen Biopharmaceuticals, Daiichi Sankyo, Ipsen, Alligator Bioscience, Bristol Myers Squibb, Jiangsu Hengrui Medicine, Shanghai Junshi Biosciences, ImmunoACT, among others. Gastroesophageal Reflux Disease Market Gastroesophageal Reflux Disease Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key GERD companies, including Phathom Pharmaceuticals, Inc., Microbiome Health Sciences, Takeda, Braintree Laboratories, AstraZeneca, among others. Gastroesophageal Reflux Disease Pipeline Gastroesophageal Reflux Disease Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GERD companies, including Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Johnson & Johnson will pay $2 billion to acquire Ambrx Biopharma and the San Diego biotechnology companys pipeline of targeted drugs for cancer.The deals announcement Monday coincides with the start of the annual J.P. Morgan Healthcare Conference, which is typically viewed as a jumping-off point for industry dealmaking in the new year. Also on Monday, Merck & Co. said it has agreed to purchase the cancer drug developer Harpoon Therapeutics, and Novartis reached a deal to buy the privately held Calypso Biotech.All told, the three transactions represent nearly $3 billion in total upfront value similar to what was announced at the beginning of last years J.P. Morgan meeting.In buying Ambrx, J&J is stocking up on a kind of drug thats newly in vogue among large pharmaceutical companies. Ambrx specializes in antibody-drug conjugates, which pair a targeting antibody with a cell-killing toxin. In theory, their design can minimize treatment side effects while delivering a potent punch to tumors.Last year, ADCs were at the center of the largest pharma deals, including Pfizers $43 billion acquisition of Seagen, an early pioneer in the field, and Mercks licensing of three experimental ADCs from Daiichi Sankyo. More recently, AbbVie paid $10.1 billion for ADC maker Immunogen.A steady drumbeat of licensing agreements accompanied those big-ticket deals, too. In a report put out Friday, J.P. Morgan analysts found that total upfront cash and equity for ADC licenses reached $4.6 billion last year, an all-time high.Ambrxs most advanced drug candidate targets a protein known as HER2 for the treatment of breast cancer. The company also has ADCs targeting PSMA for prostate cancer and CD70 for kidney cancer.J&J appears most interested in Amrbxs ADC for prostate cancer, dubbed ARX517. The pharma currently markets several drugs for prostate cancer and has made the disease a priority area of research.The results seen to date with ARX517 in [metastatic castration-resistant prostate cancer] are promising and represent a potential first- and best-in-class targeted therapy for the treatment of this aggressive disease, said Yusri Elsayed, J&Js therapeutic area head for oncology, in a statement from the company.J&J will pay $28 per Ambrx share, a more than 100% premium to the stocks closing price Friday. The deal price represents a dramatic reversal from just two years ago, when Ambrx shares traded below $1. Shares began to climb in late February and early March, when Ambrx disclosed early clinical trial data for its prostate and breast cancer therapies.Spun out of The Scripps Research Institute in 2003, Ambrx has developed a specialized technique for conjugating antibodies to the chemical linkers needed to pair the targeting proteins with toxins.The companies expect the deal, which is worth an estimated $1.9 billion net of Ambrxs cash on hand, to close in the first half of 2024.Outside of the Amrbx deal, &J currently has ADC partnerships in place with Mersana Therapeutics and Hangzhou DAC Biotechnology. '

DUBLIN, June 16, 2023 /PRNewswire/ -- The "Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029" report has been added to ResearchAndMarkets.com's offering. Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029 Report Highlights: Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029 Global & Regional Antibody Drug Conjugate Market Insight Approved Drugs Sales Insight Global & Regional, Yearly & Quarterly, 2019 -2023 Approved Antibody Drug Conjugates - Availability, Dosage & Price Insight Insight On Antibody Drug Conjugates In Clinical Trials: > 550 Drugs Insight On Commercially Approved Antibody Drug Conjugates: > 15 Drugs Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication & Phase Global Cancer Antibody Drug Conjugate Market Trends by Indication The realm of cancer treatment is experiencing a surge of innovation that may greatly change how we currently diagnose as well as treat cancer. Clinical researchers and pharmaceutical companies continue to seek innovative solutions that offer enhanced efficacy and reduced side effects. Among the ongoing significant advancements, antibody drug conjugates (ADCs) have emerged as a groundbreaker in cancer therapeutics. This rapidly expanding market is transforming the treatment landscape, offering a new therapeutic option for patients globally. Antibody drug conjugates harness the synergistic potential of monoclonal antibodies and potent cytotoxic drugs, delivering a strong strike against cancer cells. By exploiting the specificity of monoclonal antibodies, antibody drug conjugates can selectively bind to cancer antigens, increasing drug delivery directly to tumor sites. This targeted approach enables higher drug concentrations at the desired location while minimizing harm to healthy, normal tissues. The antibody drug conjugate market is experiencing remarkable growth, driven by several key factors including the increasing cancer incidence rates, rowing demand for effective and personalized treatment options and advancements in antibody engineering and drug delivery technologies are propelling the market forward. Moreover, regulatory approvals have opened the way for the commercial success of antibody drug conjugates which has further encouraged investments in the field. For instance, Adcetris and Kadcyla have been in the market for a long time and their commercial sales hold a significant share of the current antibody drug conjugate market. The growth of these antibody drug conjugates represents the significant need for this therapeutic modality. Enhertu, another antibody drug conjugate which is relatively new to the market compared to Kadcyla and Adcetris, has shown immense success commercially. With its recent approval for breast cancer indication, the sales for Enhertu have escalated rapidly. Antibody drug conjugates have welcomed a new age of targeted cancer therapy and this novel class of cancer treatment can be evaluated to have an exponential increase in terms of both commercial success as well as expansion of the global portfolio. However, the development of antibody drug conjugates has been associated with significant challenges with difficulties in manufacturing, bioconjugation and their overall development. Nevertheless, collaboration between pharmaceutical companies and academic institutions has been an important factor that has helped in overcoming these limitations, resulting in such success of antibody drug conjugates. For instance, Lantern Pharma collaborating with Germany's Bielefeld University will leverage its proprietary Artificial Intelligence platform RADR for the rapid development of novel cryptophycin antibody drug conjugates, representing an exciting new class of strong and highly directed drug candidates. It is expected that outcomes from this collaborative arrangement will pave the way for next generation antibody drug conjugated designed using AI with high efficacy, swift development with sibilant cost reduction. The future of antibody drug conjugates is expected to be closely tangled with technological innovations. Novel conjugation strategies such as site specific conjugation are also being explored to enhance stability of antibody drug conjugates, resulting in improved therapeutic outcomes. Additionally, advancements in bioconjugation techniques, payload release mechanism and drug delivery systems offer opportunities to optimize the pharmacokinetics and bio distribution of antibody drug conjugates potentially increasing their effectiveness. Antibody drug conjugates have targeted a new level of efficacy, surpassing the capabilities of traditional monoclonal antibodies and opening opportunities for market expansion. While monoclonal antibodies are highly specific in their binding to cancer cell antigens, their therapeutic impact often relies on the activation of immune responses or blocking signaling pathways. In contrast, antibody drug conjugates offer a multifaceted approach by directly delivering a potent cytotoxic payload to cancer cells, exerting a direct cell killing effect. Overall, the antibody drug conjugates market represents a groundbreaking approach to cancer treatment. As market continues to expand, patients and healthcare professionals are witnessing significant advancements. With ongoing research, technological innovations and strategic collaborations, the future of antibody drug conjugates is set to transform the global cancer therapy market. This report provides a comprehensive analysis about the currently approved antibody drug conjugates in terms of their patent, price, dosage as well as their sales and treatment cost. Furthermore, the report also provides information about the regional impact of approved antibody drug conjugates while also providing information about the possible future opportunities in the global antibody drug conjugates market. Key Topics Covered: 1. Introduction to Antibody Drug Conjugates 1.1 Overview 1.2 Historical Development of ADCs 1.3 Evolution of Antibody Drug Conjugates 2. Need of Antibody Drug Conjugates 3. Global Antibody Drug Conjugate Market Insight 3.1 Current Market Scenario (2019 -2023) 3.2 Future Market Opportunity Assessment 2029 4. Antibody Drug Conjugate Market Regional Analysis 4.1 US 4.2 China 4.3 South Korea 4.4 India 4.5 Australia 4.6 Europe 4.7 Canada 4.8 Japan 4.9 Taiwan 5. Global Cancer Antibody Drug Conjugate Market Trends by Indication 5.1 Breast Cancer 5.2 Lung Cancer 5.3 Lymphoma 5.4 Leukemia 5.5 Cervical Cancer 5.6 Urothelial Cancer 5.7 Gastric Cancer 5.8 Other Cancers 6. Approved Antibody Drug Conjugates - Availability, Dosage & Price Insight 2023 6.1 Mylotarg 6.2 Adcetris 6.3 Kadcyla 6.4 Besponsa 6.5 Lumoxiti 6.6 Polivy 6.7 Padcev 6.8 Enhertu 6.9 Trodelvy 6.10 Blenrep 6.11 Zynlonta 6.12 Tivdak 6.13 Elahere 6.14 Aidixi 6.15 Ujvira 6.16 Akalux 7. Approved Antibody Drug Conjugate Sales Insights (Global & Regional, Yearly & Quarterly, 2019 -2023) 7.1 Adcetris 7.2 Padcev 7.3 Tivdak 7.4 Polivy 7.5 Kadcyla 7.6 Besponsa 7.7 Enhertu 7.8 Trodelvy 7.9 Zynlonta 7.10 Elahere 7.11 Blenrep 8. Global Antibody Drug Conjugates Clinical Trials Insight 2023 8.1 By Phase 8.2 By Indication 8.3 By Company 8.4 By Patient Segment 8.5 By Country 9. Global Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication & Phase 9.1 Research 9.2 Preclinical 9.3 Phase-I 9.4 Phase-I/II 9.5 Phase-II 9.6 Phase-II/III 9.7 Phase-III 9.8 Preregistration 10. Marketed Cancer Antibody Drug Conjugates Clinical Insight 11. Global Cancer an Antibody Drug Conjugates Market Dynamics 11.1 Favorable Parameters 11.2 Challenges for Antibody Drug conjugates Market 12. Competitive Landscape 12.1 AbbVie 12.2 ADC Therapeutics 12.3 AstraZeneca 12.4 Bayer 12.5 BiOneCure Therapeutics 12.6 Biosion 12.7 Bio-Thera Solutions 12.8 Boehringer Ingelheim 12.9 Daiichi Sankyo Company 12.10 Duality Biologics 12.11 Exelixis 12.12 Genmab 12.13 Hangzhou DAC Biotech 12.14 Heidelberg Pharma AG 12.15 Iksuda Therapeutics 12.16 ImmunoGen 12.17 LaNova Medicines Limited 12.18 LegoChem Biosciences 12.19 Lepu Biopharma 12.20 Mersana Therapeutics 12.21 Molecular Templates 12.22 Multitude Therapeutics 12.23 NanoValent Pharmaceuticals 12.24 NewBio Therapeutics 12.25 Orum Therapeutics 12.26 ProfoundBio 12.27 Radiopharm Theranostics 12.28 Seagen 12.29 Sorrento Therapeutics 12.30 Sutro Biopharma For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets